Japan's biggest drug maker is making eyes at the US market as its patents get closer to their expiration dates. Takeda Pharmaceutical said it would pay $100 million to be Alnylam Pharmaceuticals' strategic partner in RNAi therapeutics, says the Wall Street Journal.